Achillion Pharma (ACHN) to be acquired by Alexion (ALXN)

  

 

Achillion Pharma to be acquired by Alexion (ALXN) for $6.30/share in cash + CVRs worth up to $2.00/share
To be acquired by Alexion (ALXN) for an all-cash initial consideration of approx. $930 mln, or $6.30/share; potential additional contingent considerations, which hinge on clinical and regulatory developments such as FDA approval of danicopan and ACH-5228 Phase 3 initiation, could elevate the amount payable to co's shareholders to $8.30/share. Alexion looks forward to applying its "development expertise" to co's oral Factor D inhibitors in an endeavor to unlock the approach's potential and deliver benefits to patients. The stock moves to its highest levels in almost three years.

**  ACHN  **